Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 9;16(7):1272-1281.
doi: 10.1021/acsmedchemlett.4c00595. eCollection 2025 Jul 10.

Identification of a Novel Indolizine RORγT Inverse Agonist Using the AI-Driven Drug Design Platform

Rafał A Bachorz  1 , Joanna Pastwińska  2 , Michael S Lawless  1 , David W Miller  1 , Anna Sałkowska  2 , Kaja Karaś  2 , Iwona Karwaciak  2 , Jeremy O Jones  1 , Marcin Ratajewski  2
Affiliations

Identification of a Novel Indolizine RORγT Inverse Agonist Using the AI-Driven Drug Design Platform

Rafał A Bachorz et al. ACS Med Chem Lett. .

Abstract

Automated multiparameter optimization (MPO) at the point of initial drug design is a powerful emerging approach to improve and expedite drug development. We employed the AI-driven drug design (AIDD) platform to design novel RORγT ligands optimized using QSAR activity models, machine learning ADMET properties, 3D pharmacophore similarity, and synthetic difficulty predictions. We calculated several measures of novelty postdesign and then employed multicriteria decision analysis (MCDA) to select compounds for synthesis for this important drug target. We found that 19/27 (70%) of the selected compounds inhibited RORγT activity in a cell-based assay by at least 25% at 20 μM. The most potent compound had a measured IC50 of 1.51 μM (the predicted IC50 was 1.29 μM) and demonstrated activity in human T cells. The logP, thermodynamic solubility, liver microsome clearance, fraction unbound in plasma, and MDCK permeability of this compound were measured in vitro and shown to be close to or better, e.g., higher in vitro solubility, than the values predicted by ADMET Predictor. This compound has an indolizine scaffold that has not yet been reported in the context of the RORγT receptor, demonstrating the power of MPO in the earliest stages of drug design to create novel, active molecules already possessing ADMET properties suitable for advanced lead optimization.

Keywords: RORγT; artificial intelligence; drug design; inverse agonist.

PubMed Disclaimer

References

    1. Medvedev A., Chistokhina A., Hirose T., Jetten A. M.. Genomic structure and chromosomal mapping of the nuclear orphan receptor ROR gamma (RORC) gene. Genomics. 1997;46(1):93–102. doi: 10.1006/geno.1997.4980. From NLM Medline. - DOI - PubMed
    1. Hirose T., Smith R. J., Jetten A. M.. ROR gamma: the third member of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal muscle. Biochem. Biophys. Res. Commun. 1994;205(3):1976–1983. doi: 10.1006/bbrc.1994.2902. From NLM Medline. - DOI - PubMed
    1. Ratajewski M., Walczak-Drzewiecka A., Salkowska A., Dastych J.. Upstream stimulating factors regulate the expression of RORgammaT in human lymphocytes. J. Immunol. 2012;189(6):3034–3042. doi: 10.4049/jimmunol.1200519. From NLM Medline. - DOI - PubMed
    1. Kang H. S., Angers M., Beak J. Y., Wu X., Gimble J. M., Wada T., Xie W., Collins J. B., Grissom S. F., Jetten A. M.. Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics. 2007;31(2):281–294. doi: 10.1152/physiolgenomics.00098.2007. From NLM Medline. - DOI - PubMed
    1. Takeda Y., Kang H. S., Freudenberg J., DeGraff L. M., Jothi R., Jetten A. M.. Retinoic acid-related orphan receptor gamma (RORgamma): a novel participant in the diurnal regulation of hepatic gluconeogenesis and insulin sensitivity. PLoS Genet. 2014;10(5):e1004331. doi: 10.1371/journal.pgen.1004331. From NLM Medline. - DOI - PMC - PubMed

LinkOut - more resources